{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:49:53Z","timestamp":1791319793291,"version":"4.3.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvoice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Voice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jvoice.2026.09.031","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:50:50Z","timestamp":1791316250000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune Checkpoint Inhibitors and Laryngological Outcomes in Patients with Non-Head and Neck Cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5259-5395","authenticated-orcid":false,"given":"Neil S.","family":"Dogra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5146-6319","authenticated-orcid":false,"given":"Robert T.","family":"Sataloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvoice.2026.09.031_bib1","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jvoice.2026.09.031_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m736","article-title":"Autoimmune complications of immunotherapy: pathophysiology and management","author":"Chan","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jvoice.2026.09.031_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/imr.13270","article-title":"The evolving landscape of immune-related adverse events that follow immune checkpoint immunotherapy in cancer patients","volume":"318","author":"Villani","year":"2023","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jvoice.2026.09.031_bib4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/imr.13240","article-title":"Mediators and mechanisms of immune checkpoint inhibitor-associated myocarditis: Insights from mouse and human","volume":"318","author":"Gong","year":"2023","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jvoice.2026.09.031_bib5","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/ijc.35347","article-title":"How many people in the US are eligible for and respond to checkpoint inhibitors: an empirical analysis","volume":"156","author":"Haslam","year":"2025","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jvoice.2026.09.031_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/bcp.70700","article-title":"Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018\u20132024: A national retrospective cohort study","author":"Mueller","year":"2026","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jvoice.2026.09.031_bib7","series-title":"Immunotherapy. Vol 1244. Advances in Experimental Medicine and Biology","first-page":"295","article-title":"Immune-Related Oral, Otologic, and Ocular Adverse Events","author":"Srivastava","year":"2020"},{"key":"10.1016\/j.jvoice.2026.09.031_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001675","article-title":"Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma","volume":"8","author":"Rosner","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jvoice.2026.09.031_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/CJI.0000000000000310","article-title":"Bilateral vocal cord paralysis due to an immune-related adverse event of nivolumab: a case report","volume":"43","author":"Willegers","year":"2020","journal-title":"J Immunother"},{"key":"10.1016\/j.jvoice.2026.09.031_bib10","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1002\/lary.31492","article-title":"Immune checkpoint inhibitor induced supraglottitis: a case series","volume":"134","author":"Gascon","year":"2024","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.09.031_bib11","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jvoice.2022.12.028","article-title":"Laryngeal mucous membrane pemphigoid as an immune-related adverse effect of pembrolizumab treatment","volume":"39","author":"Lagos-Villaseca","year":"2025","journal-title":"J Voice"},{"key":"10.1016\/j.jvoice.2026.09.031_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578679","article-title":"Paraneoplastic bilateral vocal cord paralysis in a patient with anti-Hu syndrome after receiving nivolumab: case report and literature review","volume":"406","author":"Erdo\u011fan","year":"2025","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jvoice.2026.09.031_bib13","first-page":"S1","article-title":"Clinical practice guideline: Hoarseness (Dysphonia) (Update)","volume":"158","author":"Stachler","year":"2018","journal-title":"Otolaryngol Neck Surg"},{"key":"10.1016\/j.jvoice.2026.09.031_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvoice.2026.06.013","article-title":"I go but i don\u2019t participate\u201d: a scoping review with thematic synthesis of the experiences of voice disorders in adulthood","author":"Ruhle","year":"2026","journal-title":"J Voice"},{"key":"10.1016\/j.jvoice.2026.09.031_bib15","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1002\/lary.21058","article-title":"Self-reported impact of dysphonia in a primary care population: an epidemiological study","volume":"120","author":"Cohen","year":"2010","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.09.031_bib16","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1007\/s00455-022-10427-3","article-title":"Pneumonia, mortality, and other outcomes associated with unsafe swallowing detected via fiberoptic endoscopic evaluation of swallowing (FEES) in patients with functional oropharyngeal dysphagia: a systematic review and meta-analysis","volume":"37","author":"Giraldo-Cadavid","year":"2022","journal-title":"Dysphagia"},{"key":"10.1016\/j.jvoice.2026.09.031_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13930","article-title":"Dysphagia in hospitalized patients: prevalence, related factors and impact on aspiration pneumonia and mortality","volume":"53","author":"Bosch","year":"2023","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jvoice.2026.09.031_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953761","article-title":"Safety and efficacy of programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the treatment of cancer: an overview of systematic reviews","volume":"13","author":"Ou","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jvoice.2026.09.031_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.4971","article-title":"Uptake and survival outcomes following immune checkpoint inhibitor therapy among trial-ineligible patients with advanced solid cancers","volume":"7","author":"Parikh","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jvoice.2026.09.031_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","article-title":"Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes","volume":"23","author":"Farina","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jvoice.2026.09.031_bib21","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jvoice.2026.09.031_bib22","doi-asserted-by":"crossref","first-page":"e866","DOI":"10.1212\/WNL.0000000000011340","article-title":"Cranial nerve disorders associated with immune checkpoint inhibitors","volume":"96","author":"Vogrig","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jvoice.2026.09.031_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2026.113053","article-title":"Unilateral vocal cord paralysis: a comprehensive guide for general radiologists","volume":"203","author":"Simone","year":"2026","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.jvoice.2026.09.031_bib24","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1002\/hed.27646","article-title":"Orofacial complications from immune checkpoint inhibitors: a retrospective analysis from two academic medical centers","volume":"46","author":"Al-Eryani","year":"2024","journal-title":"Head Neck"},{"key":"10.1016\/j.jvoice.2026.09.031_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/odi.13964","article-title":"Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"28","author":"Klein","year":"2022","journal-title":"Oral Dis"},{"key":"10.1016\/j.jvoice.2026.09.031_bib26","first-page":"1796","article-title":"Oral side effects of immune checkpoint inhibitor therapy (ICIT): an analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women\u2019s Hospital, and the Dana-Farber","volume":"127","author":"Xu","year":"2021","journal-title":"Cancer Inst 2011 2019 Cancer"},{"key":"10.1016\/j.jvoice.2026.09.031_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11523-017-0495-4","article-title":"Immune checkpoint inhibitor-induced colitis: diagnosis and management","volume":"12","author":"Prieux-Klotz","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.jvoice.2026.09.031_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2016.4443","article-title":"Severe oral ulcers associated with nivolumab treatment","volume":"153","author":"Namiki","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jvoice.2026.09.031_bib29","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/jjco\/hyag016","article-title":"Pembrolizumab-induced pan-airway mucositis with a cobblestone-like appearance: a case report","volume":"56","author":"Ikeda","year":"2026","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jvoice.2026.09.031_bib30","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.21.01208","article-title":"Salivary gland hypofunction and\/or xerostomia induced by nonsurgical cancer therapies: ISOO\/MASCC\/ASCO guideline","volume":"39","author":"Mercadante","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvoice.2026.09.031_bib31","doi-asserted-by":"crossref","first-page":"896","DOI":"10.6004\/jnccn.2020.7675","article-title":"Clinicopathologic features, treatment response, and outcomes of immune checkpoint inhibitor-related esophagitis","volume":"19","author":"Panneerselvam","year":"2021","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"10.1016\/j.jvoice.2026.09.031_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/14740338.2024.2416539","article-title":"Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases","volume":"25","author":"Rabbani","year":"2026","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jvoice.2026.09.031_bib33","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.oooo.2025.09.006","article-title":"Orofacial adverse events associated with immune checkpoint inhibitors: using a large real-world dataset","volume":"141","author":"Oyewole","year":"2026","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.jvoice.2026.09.031_bib34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.otc.2007.11.011","article-title":"Laryngitis: types, causes, and treatments","volume":"41","author":"Dworkin","year":"2008","journal-title":"Otolaryngol Clin North Am"},{"key":"10.1016\/j.jvoice.2026.09.031_bib35","doi-asserted-by":"crossref","first-page":"E140","DOI":"10.1002\/lary.28038","article-title":"Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer","volume":"130","author":"Pelster","year":"2020","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.09.031_bib36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2022.11.001","article-title":"Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors","volume":"179","author":"Velev","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jvoice.2026.09.031_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.31417","article-title":"Cancer knocks you out by fasting: cachexia as a consequence of metabolic alterations in cancer","volume":"240","author":"Cortellino","year":"2025","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jvoice.2026.09.031_bib38","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvoice.2026.09.031_bib39","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00262-023-03436-0","article-title":"Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients","volume":"72","author":"\u00d6zdemir","year":"2023","journal-title":"Cancer Immunol Immunother CII"}],"container-title":["Journal of Voice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0892199726005072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0892199726005072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:50:55Z","timestamp":1791316255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0892199726005072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"alternative-id":["S0892199726005072"],"URL":"https:\/\/doi.org\/10.1016\/j.jvoice.2026.09.031","relation":{},"ISSN":["0892-1997"],"issn-type":[{"value":"0892-1997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitors and Laryngological Outcomes in Patients with Non-Head and Neck Cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Voice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvoice.2026.09.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The Voice Foundation.","name":"copyright","label":"Copyright"}]}}